Introduction {#s0001}
============

Shigellosis, a disease caused by *Shigella*, is endemic in developing countries due to a lack of hygienic drinking water sources, malnutrition and the high cost of antibiotic therapy. There are more than 40 *Shigella* serotypes, which are classified based on O antigen polysaccharide diversity. *S. flexneri* and *S. dysentery* are the causative agents of endemic and epidemic dysentery, particularly in children under 5 y old in developing countries. Shigellosis often causes severe symptoms and may lead to death.[@cit0001] An estimated 80--160 million annual cases of dysentery occur worldwide, which lead to approximately one million deaths annually.[@cit0005] To date, no effective vaccine prevents the disease caused by *Shigella*. In addition, the rapid and broad global spread of antibiotic resistance has been reported among different serotypes of *Shigella*. Thus, the World Health Organization (WHO) has prioritized the development and production of an efficient vaccine to globally protect people against *Shigella*. Immunogenic *Shigella* surface proteins that are conserved among different serotypes are thought to be capable of inducing broad-spectrum protection against multiple *Shigella* serotypes.[@cit0004] Invasion plasmid antigen B (IpaB) is a *Shigella* surface protein located at the very top of its type three secretory system (TTSS), and it is a key virulence factor of *Shigella*.[@cit0008] This protein alone may not be capable of inducing a protective immune response against *Shigella*, but it has been recently used, along with other *Shigella* proteins, to generate effective vaccine candidates.[@cit0004] Since 2012, the combinations of IpaB/IpaD and IpaB/GroEL have been reported aspotential vaccine candidates capable of inducing protection against experimental *Shigella* infections in mice.[@cit0007]

*Clostridium perfringens* enterotoxin (CPE) consists of two functional domains: a cytotoxic N-terminal domain and a non-toxic C-terminal domain (C-CPE). The C-terminal domain of CPE is known to be capable of binding to claudin-3 and claudin-4 molecules at the surface of some mammalian cells. The strong attachment of the C-CPE to claudin-3 and -4 on human intestinal epithelial cells causes this peptide to aggregate on the luminal sides of intestinal epithelial cells, allowing it to act as a biological and mucosal adjuvant for orally administered drugs and vaccines. Previous studies have indicated that these attachments eventually lead to the transfer of the C-CPE, and likely any protein fused to it, into the cytoplasm of intestinal epithelial cells through receptor mediated endocytosis.[@cit0013]

Claudin-3 and -4 molecules belong to the claudin receptor molecule family.[@cit0014] Claudin-3 is localized on the apical surfaces of villi and cryptic epithelial cells of the human small and large intestines. Moreover, these molecules are localized on the entire apical surfaces of follicle associated epithelia (FAEs) in the human intestinal tract. However, claudin-4, another receptor for the C-CPE, is found more frequently on the basolateral surfaces of epithelial cells in the intestinal villi. Claudin-4 is also found on the apical surfaces of FAEs in Peyer\'s patches and on the apical surfaces of cecal patches in the human large intestine.[@cit0016]

The aim of the current study is to design a chimeric IpaB-C-CPE protein for use in the development of a vaccine to combat *Shigella* infections. To the best of our knowledge, this report is the first to design a chimeric IpaB-C-CPE for any biological or medical purpose.

Results {#s0002}
=======

The amino acid sequences of 537 chimeric IpaB-linker-CPE~290--319~ variants generated using 537 different peptide linkers to connect IpaB~240--460~ to CPE~290--319~ were obtained using an in silico sequence conversion tool. Furthermore, the amino acid sequences of IpaB-CPE~184--319~ and IpaB-CPE~194--319~ were obtained successfully using the abovementioned software. All the obtained amino acid sequences were analyzed by phyre2 software, and 3D structures of the recombinant proteins were downloaded as 539 PBD files. The 3D structures of 537 chimeric proteins were compared with the 3D structures of native IpaB~240--460~ and CPE~290--319~ using TM-align software, and the rate of similarity index between these proteins and recombinant IpaB-linker-CPE~290--319~ was calculated by measuring the TM-score. The obtained results showed that all 537 linkers had impaired CPE~290--319~ and IpaB~240--460~ 3D structures. Using TM-align software from the Zhang lab, the 3D structures of CPE~184--319~ and CPE~194--319~ were found to exhibit considerable similarity to their corresponding domains in IpaB-CPE~184--319~ (TM-score: 0.97) and IpaB-CPE~194--319~ (TM-score: 0.99), respectively ([Fig. 1](#f0001){ref-type="fig"}). Figure 1.Protein 3D structure alignments generated by the UCSF Chimera package.[@cit0038] (A) Structural alignment of IpaB-CPE~194--319~ (in white) with native CPE~194--319~ (in black). (B) 3D structure of IpaB-CPE~184--319~ (in white) aligned with the 3D structure of native CPE~184--319~ (in black).

IpaB-CPE~194--319~ was predicted to be a stable 38.5 KDa protein with an estimated half-life of more than 10 hours in *E. coli*. The aliphatic and grand average of hydropathicity (GRAVY) indices of IpaB-CPE~194--319~ were predicted by ExPASy ProtParam online software to be 109.66 and 0.117, respectively. The results obtained from IpaB-CPE~194--319~ secondary structure analysis revealed a high percentage of alpha helices and low percentages of beta strands and disordered regions. In addition to these secondary structures, a moderate percentage of transmembrane helices was predicted (residues 72--184).

In total, 150 B-cell lineal epitopes (5--20 amino acids) exhibiting FBCpred scores greater than 0.7 were predicted within the IpaB-CPE~194--319~ structure (Supplementary Table 1). Among all 150 lineal epitopes within the chimeric protein, 62 B-cell epitopes fit within residues 1--221, which correspond to the IpaB~240--460~ structure. Moreover, 28 B-cell conformational epitope residues were predicted by the DiscoTope server within full-length IpaB-CPE~194--319~ ([Table 1](#t0001){ref-type="table"}). Among all predicted conformational epitope residues, 13 epitope residues were predicted within residues 1--221. Table 1.IpaB-CPE~194--319~ B-cell conformational epitopes predicted by the DiscoTope server. In total, 28 epitope residues were identified within IpaB-CPE~194--319~.Epitope positionEpitope sequenceContact numberDiscoTope score1--4MQKS1, 8, 6, 0−0.257, −1.600, −2.288, −2.43325N0−2.84045K11−3.58547E11−2.467152G0−2.651154D5−3.627217--218SQ5, 5−2.878, −3.606220--224DDLDI6, 4, 9, 0, 3−2.641, −1.886, −3.211, −1.327, −2.379248--249PA0, 9−1.307, −2.740262P5−3.416309--312DGVK5, 4, 0, 4−2.702, −1.851, −1.469, −2.795334--338SYSGN1, 20, 0, 5, 9−1.462, −2.922, 0.607, −0.292, −1.866

Codon optimization of *ipaB-c-cpe* (encoding IpaB-CPE~194--319~) was performed using OPTIMIZER according to an *E. coli* codon usage table provided by the Kazusa codon usage database. The codon adaptation indices (CAIs) of the codon-optimized and non-optimized recombinant genes were analyzed by both the OPTIMIZER and GenScript rare codon analysis tools. The results showed a significant increase in the CAI following codon optimization. The CAI value determined by OPTIMIZER following codon optimization was 1, whereas the CAI values calculated by the GenScript rare codon analysis tool were 0.62 and 0.94 prior to and following codon optimization, respectively ([Fig. 2](#f0002){ref-type="fig"}). Figure 2.Codon adaptation index (CAI) values of *ipaB-c-cpe*. (A) A CAI of 0.62 was calculated by the GenScript rare codon analysis tool before codon optimization. (B) A CAI of 0.94 was calculated by the GenScript rare codon analysis tool after codon optimization.

mRNA secondary structure prediction of ipaB-c-cpe showed that the most stable mRNA structure had a ΔG equal to −311.2 kcal/mol, and no stable hairpins or pseudo knots were observed in this predicted structure ([Fig. 3](#f0003){ref-type="fig"}). Figure 3.Prediction of *ipaB-c-cpe* mRNA secondary structure. No long stable hairpins or pseudo knots were observed at the 5′ of the predicted structure.

Discussion {#s0003}
==========

Currently, there is no available licensed vaccine against *Shigella*; however, several ongoing studies are focusing on *Shigella* surface proteins that are common among different serotypes of this microorganism as potential vaccine candidates.[@cit0004] IpaB, one of these surface proteins, has been shown to be capable of inducing an antibody response in humans. Moreover, IpaB-specific antibodies have been shown to be negatively correlated with shigellosis severity in humans.[@cit0017] Recently, a *Lactococcus lactis* bacterium-like particles (BLP) vaccine candidate harboring IpaB and IpaD was successfully designed and used in adult and newborn mouse studies. Protective immune responses against *S. flexneri* and *S. sonnei* were generated in 90% and 80% of the adult mice and 90% and 44% of newborn mice, respectively, following immunization with BLP-IpaB/D.[@cit0018] IpaB fused to GroEL (IpaB-GroEL) has been investigated in a more recent study as a vaccine candidate against shigellosis. Interestingly, the immunization of mice with chimeric IpaB-GroEL resulted in the protection of 90--95% of mice following lethal challenges with *S. flexneri, S. boydii* and *S. sonnei*.[@cit0019] The present study focuses on the design of a novel chimeric protein consisting of a variant of IpaB, IpaB~240--460~, which is an immunogenic surface protein conserved among different serotypes of *Shigella*, fused to the C-terminus of the *Clostridium perfringens* enterotoxin.

Residues 240--280 of IpaB are involved in protein stability and folding, while residues 313--333 and 399--419 form two large globular domains located at the Tip Complex (TC) of the TTSS that are likely responsible for any contact of IpaB with the host cell as well as the penetration of this protein into the host cell membrane.[@cit0020] Our designed chimeric protein contains amino acid residues from IpaB, as well as their respective domains, that are mostly in contact with host cells and the environment and are essential for the initiation of *Shigella* invasion into epithelial cells. Therefore, the neutralization of these structures and domains by the induction of mucosal immunity likely leads to the inhibition of *Shigella* invasion and the prevention of the disease caused by these bacteria.

The presence of the C-CPE in the structure of our designed chimeric protein makes this chimeric protein better able to induce a mucosal immune response, as the C-CPE exhibits adjuvant properties when administered on mucosal surfaces.[@cit0013] Several C-CPE variants, such as CPE~168--319~, CPE~171--319~, CPE~184--319~, CPE~194--319~ and CPE~290--319~, have been shown to be capable of binding to claudin family proteins.[@cit0015] Among these variants, CPE~290--319~ is the most frequently studied. This variant is sufficient for binding to some claudin proteins with an affinity comparable to that of native CPE.[@cit0024] Thus, the first chimeric protein designed in this study was IpaB-CPE~290--319~.

To preserve the native conformations and functions of IpaB~240--460~ and CPE~290--319~ in the structure of our first designed chimeric protein, different peptide linkers were placed between IpaB~240--460~ and CPE~290--319~. Then, the 3D structures of 537 recombinant IpaB-linker-CPE~290--319~ proteins differing in their peptide linkers were analyzed by TM-align software to determine the linker sequence resulting in the highest TM-score. The TM-score varies between 0 and 1. A TM-score of 1 indicates perfect similarity between the 3D structures of two proteins. As TM-align software compares uploaded protein data bank (PDB) files to the 3D structures of different proteins and peptides in several protein databases, and there is no 3D structure related to full-length IpaB or the C-terminus of IpaB, TM-align software was unable to determine any valid TM-scores for the comparisons of the IpaB-linker-CPE~290--319~ variants to IpaB~240--460~. However, we successfully used this software to compare our designed protein with CPE~290--319~. The similarity between IpaB-linker-CPE~290--319~ and CPE~290--319~ 3D structures was determined to be random, with a TM-score of 0.39, and all the analyzed linkers were determined to cause significant disorganization in the 3D structure of CPE~290--319~.

In addition to the efforts described above, the 3D structures of IpaB-CPE~290--319~, IpaB-CPE~184--319~ and IpaB-CPE~194--319~ were compared to the 3D structures of CPE~290--319~, CPE~184--319~ and CPE~194--319~, respectively. The highest TM-score, 0.99, was achieved for the alignment of the IpaB-CPE~194--319~ and CPE~194--319~ 3D structures, showing a high degree of similarity between these two 3D structures. Bioinformatic analysis also showed excellent similarity between the 3D structures of IpaB-CPE~184--319~ and CPE~184--319~, with a TM-score of 0.97.

Both CPE~194--319~ and CPE~184--319~ have been shown to be capable of high-affinity specific binding to claudin-3 and -4 at the tight junctions of intestinal epithelial cells without inducing cytotoxicity.[@cit0023] Although CPE~290--319~ is known as the claudin-binding domain of the CPE, this variant of the C-CPE is not able to bind claudin-4 without the presence of its N-terminal domain. However, CPE~184--319~ and CPE~194--319~, containing longer N-terminal regions than CPE~290--319~, are capable of binding to claudin-4 more strongly, likely because they contain more of the functional domains required to bind their receptor molecules and claudins.[@cit0023] According to previous results and the *in silico* analysis performed in the current study, the N-terminal domains of CPE~184--319~ or CPE~194--319~ are likely involved in the folding of these proteins, as they are necessary for the formation of a strong attachment to claudin-4.

Based on our findings, many natural and synthetic peptide linkers with different physical and chemical properties were unable to provide the physicochemical interactions necessary to correctly fold CPE~290--319~, which is a requirement for it to bind claudin-4 molecules. Thus, although CPE~290--319~ has been frequently used as a natural ligand for the attachment of other molecules to targeted cells,[@cit0013] The results of this study indicate that CPE~194--319~ and CPE~184--319~ are better suited to this purpose. Both of these C-CPE variants have been successfully tested as absorption enhancers for delivering biologically active peptides to pulmonary, nasal and jejunal tissues. CPE~184--319~ is capable of enhancing the mucosal absorption of dextran, a model drug, approximately 400--fold more than sodium caprate, a common clinical absorption enhancer. CPE~194--319~ was shown to have similar absorption enhancing properties, while CPE~289--319~ was shown to have no enhancing effect on the absorption of dextran. However, the low solubility of CPE~184--319~ limits its application as a mucosal absorbent. The solubility of CPE~194--319~ has been shown to be 30--fold greater than that of CPE~184--319~, making it more suitable for use as a mucosal absorbent than CPE~184--319~.[@cit0023]

The physical and chemical properties of chimeric IpaB-CPE~194--319~ were predicted by the ExPASy ProtParam server. The isoelectric point (pI) value was predicted to be lower than 7, which indicates the intrinsic acidity of the designed protein. The approximate low molecular weight of the designed protein decreases the probability of inclusion body formation consequent to its expression in *E. coli*. In addition, its estimated half-life of more than 10 hours in *E. coli* suggests an enhanced probability of the large-scale production and purification of this protein in *E. coli* without significant loss of its structure and activity. The high aliphatic index of chimeric IpaB-CPE~194--319~ shows the high stability of this protein across a wide range of temperatures. The positive predicted GRAVY value indicates the hydrophobic nature of this designed protein.

As a vaccine candidate against *Shigella* infections, IpaB-CPE~194--319~ is designed to induce mucosal antibody production to prevent IpaB-mediated *Shigella* invasion. The B-cell epitope prediction conducted in this study determined 150 lineal B-cell epitopes (5--20 amino acids in length) and 28 conformational B-cell epitope residues in the chimeric IpaB-CPE~194--319~. Among these, 62 lineal B-cell epitopes and 13 conformational B-cell epitope residues fit within the IpaB domain of the IpaB-CPE~194--319~ chimeric protein. According to these B-cell epitope prediction results, we assume that IpaB-CPE~194--319~ is theoretically capable of inducing a mucosal antibody response in the human intestinal tract against several IpaB epitopes. The abundance of predicted IpaB epitopes enhances the probability that chimeric IpaB-CPE~194--319~ can induce a protective humoral immune response.

Codon optimization of the recombinant protein was conducted by OPTIMIZER to enhance its further expression levels in *E. coli*. To calculate the CAI of the designed *ipaB-c-cpe* gene, two web-based programs, OPTIMIZER and the GenScript rare codon analysis tool, were used. The CAI is associated with the expression level of the desired protein and varies between 0 and 1. Genes with CAI values close to 1.0 and G/C contents between 30% and 70% are predicted to be ideally expressed. The CAI value of non-optimized *ipaB-c-cpe* was calculated to be 0.62 by the GenScript rare codon analysis tool. The values for the codon-optimized *ipaB-c-cpe* were 1.00 and 0.94, as calculated by OPTIMIZER and the GenScript rare codon analysis tool, respectively. The G/C contents of *ipaB-c-cpe* were also optimized to 51.61% and 42.95%, respectively, using OPTIMIZER. The CAI and G/C content values of the optimized genes indicate an enhanced probability of the high-yield expression of IpaB-CPE~194--319~ in *E. coli*.

Its predicted mRNA secondary structure indicates that the *ipaB-c-cpe* gene will be transcribed into a stable mRNA. The predicted mRNA structure does not include any translation inhibitory structures such as pseudo knots or long stable hairpins. Therefore, the predicted mRNA is theoretically capable of being translated into IpaB-CPE~194--319~ in *E. coli* cells.

This study describes the successful *in silico* design of a novel IpaB-CPE~194--319~ chimeric protein that is a potential vaccine candidate against *Shigella* infections. The obtained results show that, in comparison to CPE~290--319~, two other variants of the C-CPE, CPE~184--319~ and CPE~194--319~, are better able to preserve their natural 3D structures and to form stronger attachments to their natural ligands when they are linked to the C-terminal regions of other proteins. This ability may be a consequence of extra domains (184--289 and 194--289) that are involved in correct folding by CPE, CPE~184--319~ and CPE~194--319~. However, more in-depth studies are required to validate the results obtained in this study from the *in silico* analyses of different chimeric proteins containing different variants of the C-CPE. Furthermore, *in vitro* expression and purification of the designed IpaB-CPE~194--319~, followed by *in vitro* and *in vivo* evaluation of the immune response to this protein are proposed to determine the potential of this newly designed protein as a vaccine against shigellosis.

Materials and methods {#s0004}
=====================

Sequence analysis {#s0004-0001}
-----------------

To design the IpaB-C-CPE encoding gene, nucleotides 718--1380 of the full-length *ipaB* gene (NCBI accession number NC_004851.1) and a 5′ fragment of the *cpe* gene (NCBI accession number NC_008262.1) were used. The 5′ fragment of the *cpe* gene was chosen from the sequences encoding CPE~290--319~, CPE~194--319~ and CPE~184--319~ as is described in the construct design section. All amino acid sequences were obtained by converting their respective nucleotide sequences using an in silico sequence conversion tool (<http://in-silico.net/tools/biology/sequence_conversion>).

Construct design {#s0004-0002}
----------------

To construct a chimeric protein resembling the native folding and function of the respective regions of IpaB and the C-CPE, 537 derivatives of chimeric IpaB-linker-CPE~290--319~ constructs varying in their linker moieties were analyzed *in silico*. The amino acid sequences of all 537 natural and synthetic linkers were adapted from Klein et al., 2014 (for a review, see [@cit0031]) and two protein linker databases \[(<http://www.ibi.vu.nl/programs/linkerdbwww>) and (<http://parts.igem.org/Protein_domains/Linker>)\] (Supplementary Table 2). In addition to these 537 derivatives of IpaB-linker-CPE~290--319~, three other variants of IpaB-C-CPE were designed: IpaB-CPE~290--319~, IpaB-CPE~184--319~ and IpaB-CPE~194--319~.

3D. structure analysis {#s0004-0003}
----------------------

Three dimensional structures of 537 different IpaB-linker-CPE~290--319~ variants were obtained as PDB files by introducing the amino acid sequences of all 537 chimeric proteins to the Protein Homology/analogY Recognition Engine (Phyre2) ([http://www.sbg.bio.ic.ac.uk/∼phyre2/html/page.cgi?id=index](http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?id=index)).[@cit0032] In addition, PDB files containing 3D structures of IpaB~240--460~, CPE~184--319~, CPE~194--319~, CPE~290--319~, IpaB-CPE~290--319~, IpaB-CPE~184--319~ and IpaB-CPE~194--319~ without any linkers were created. Afterward, residue to residue alignments of the 3D structures of the chimeric proteins with native IpaB~240--460~ and CPE~290--319~ were performed using TM-align to analyze the similarity of the 3D structures of the relevant proteins based on their TM-scores (<http://zhanglab.ccmb.med.umich.edu/TM-align>).[@cit0033] The 3D structures of IpaB-CPE~184--319~ and IpaB-CPE~194--319~ were also compared to CPE~184--319~ and CPE~194--319~, respectively. The chimeric protein most closely resembling the native structure of the C-CPE was selected for further analysis.

Physical and chemical parameters and secondary structure {#s0004-0004}
--------------------------------------------------------

The physical and chemical properties of IpaB-CPE~194--319~, including its theoretical pI, estimated half-life, instability index, aliphatic index and GRAVY, were predicted using ExPASy ProtParam online software (<http://web.expasy.org/protparam/>). Secondary structures and probable transmembrane helices of IpaB-CPE~194--319~ were predicted using Phyre2 web-based software.

B-cell epitope prediction {#s0004-0005}
-------------------------

IpaB-CPE~194--319~ continuous/lineal B-cell epitopes (5--20 amino acids) were predicted through flexible length epitope prediction (FBCpred) using the BCPREDS server (<http://ailab.ist.psu.edu/bcpred/predict.html>).[@cit0034] IpaB-CPE~194--319~ discontinuous/conformational B-cell epitopes were analyzed by uploading the 3D structure of chimera to the Disco Tope server (<http://www.cbs.dtu.dk/services/DiscoTope/>).[@cit0035]

Codon optimization {#s0004-0006}
------------------

The amino acid sequence of IpaB-CPE~194--319~ was then converted back to a nucleotide sequence using an in silico sequence conversion tool (<http://in-silico.net/tools/biology/sequence_conversion>). The nucleotide sequence of recombinant *ipaB-c-cpe* was codon optimized to be expressed in *E. coli* using OPTIMIZER (<http://genomes.urv.es/OPTIMIZER>).[@cit0036] An *E. coli* codon usage table was adapted from a codon usage database ([www.kazusa.or.jp/codon](http://www.kazusa.or.jp/codon)). The CAI, which is directly related to the expression level of the desired gene, was analyzed by both OPTIMIZER and the GenScript rare codon analysis tool (<http://www.genscript.com/cgibin/tools/rare_codon_analysis>) to determine the expression efficiency of the recombinant gene in *E. coli*.

mRNA secondary structure {#s0004-0007}
------------------------

The secondary structure of *ipaB-c-cpe* messenger RNA was predicted using the RNAstructure Web Server (<http://rna.urmc.rochester.edu/RNAstructureWeb>), and the presence of hairpins and pseudo knots at the 5′ end of the mRNA were analyzed.[@cit0037]
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